Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study

Circulation

Volumn 110, Issue 6, 2004, Pages 674-678

  Pasceri, Vincenzo ^a   Patti, Giuseppe ^b   Nusca, Annunziata ^b   Pristipino, Christian ^a   Richichi, Giuseppe ^a   Di Sciascio, Germano ^b  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Angina; Angioplasty; Myocardial infarction; Stents; Trials

Indexed keywords

ATORVASTATIN; CREATINE KINASE MB; MYOGLOBIN; PLACEBO; STATINE DERIVATIVE; TROPONIN I;

ADULT; AGED; ANGIOPLASTY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS;

AGED; ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; BIOLOGICAL MARKERS; CORONARY STENOSIS; CREATINE KINASE; CREATINE KINASE, MB FORM; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISOENZYMES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOGLOBIN; PREMEDICATION; PROSPECTIVE STUDIES; PYRROLES; STENTS; TREATMENT OUTCOME; TROPONIN I;

EID: 4043133008     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000137828.06205.87     Document Type: Article

References (32)

1. Klein LW, Kramer BL, Howard E, et al. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol. 1991;17:621-626.
2. Abdelmeguid AE, Topol EJ, Whitlow PL, et al. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation. 1996;94:1528-1536.
3. Brener SJ, Ellis SG, Schneider J, et al. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J. 2002;23:869-876.
4. Nallamothu BK, Bates ER. Periprocedural myocardial infarction and mortality: causality versus association. J Am Coll Cardiol. 2003;42:1412-1414.
5. Ioannidis JPA, Karvouni E, Katritis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous intervention. J Am Coll Cardiol. 2003;42:1406-1411.
6. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Sinvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
7. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
8. Serruys PW, De Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287:3215-3222.
9. Herrmann J, Lerman A, Baumgart D, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation. 2002;106:2180-2183.
10. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002;105:691-696.
11. Ellis SG, Chew D, Chan A, et al. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation. 2002;106:1205-1210.
12. Uettwiller-Geiger D, Wu AH, Apple FS, et al. Multicenter evaluation of an automated assay for troponin I. Clin Chem. 2002;48:869-876.
13. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol. 2000;36:959-969.
14. Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation. 2003;107:1750-1756.
15. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
16. Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete micro-infarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation. 2001;103:2780-2783.
17. Kurz DJ, Naegeli B, Bertel O. A double-blind, randomized study of the effect of immediate intravenous nitroglycerin on the incidence of post-procedural chest pain and minor myocardial necrosis after elective coronary stenting. Am Heart J. 2000;139:35-43.
18. Wang FW, Osman A, Otero J, et al. Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Circulation. 2003;107:2914-2919.
19. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet. 1998;352:87-92.
20. Desmet W, Dens J, Coussement P, et al. Does adenosine prevent myocardial micronecrosis following percutaneous coronary intervention? The ADELINE pilot trial. Heart. 2002;88:293-295.
21. Harris BM, Nageh T, Marsden JT, et al. Comparison of cardiac troponin-T and I and CK-MB for the detection of minor myocardial damage during interventional cardiac procedures. Ann Clin Biochem. 2000;37:764-769.
22. Garbarz E, lung B, Lefevre G, et al. Frequency and prognostic value of cardiac troponin-I elevation after coronary stenting. Am J Cardiol. 1999;84:515-518.
23. Fuchs S, Kornowski R, Mehran R, et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol. 2000;85:1077-1082.
24. Ricciardi MJ, Davidson CJ, Gubernikoff G, et al. Troponin-I elevation and cardiac events after percutaneous coronary intervention. Am Heart J. 2003;145:522-528.
25. Pasceri V, Chang JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in endothelial cells by anti-atherosclerotic drugs. Circulation. 2001;103:2531-2534.
26. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
27. Patti G, Di Sciascio G, D'Ambrosio A, et al. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2002;89:372-376.
28. Walter DH, Fichtlscherer S, Sellwig M, et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol. 2001;37:839-846.
29. Jones SP, Lefer DJ. Cardioprotective action of acute HMG-CoA reductase inhibition in the setting of myocardial infarction. Acta Physiol Scand. 2001;173:139-143.
30. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15:247-251.
31. Wassmann S, Faul A, Hennen B, et al. Rapid effect of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibition on coronary endothelial function. Circ Res. 2003;93:e98-e103.
32. Correia LC, Sposito AC, Lima JC, et al. Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction. Am J Cardiol. 2003;92:298-301.